LA JOLLA, Calif., April 8, 2009 -- Investigators at Burnham Institute for Medical Research (Burnham) have deciphered a large percentage of the total protein complement (proteome) in Schizosaccharomyces pombe (S. pombe) fission yeast.
Laurence Brill, Khatereh Motamedchaboki, Ph.D. and lead investigator Dieter Wolf, Ph.D., developed the novel method, used to identify 4,600 proteins in the organism, using an array of sophisticated techniques. The research was published online on March 9 in the journal Methods.
"Analysis of the proteome of an organism tells us so much more than simple DNA sequence analysis," said Dr. Wolf. "Proteome analysis gives us a snapshot of what proteins are being expressed in the cell at any given point in time. This can tell us how protein expression changes in response to certain stimuli and in disease states, which may help identify new biomarkers for diseases. We are now applying the methodology to protein profiling of human stem cells in collaboration with Burnham's stem cell program director, Evan Snyder."
The method developed by Burnham scientists involved digestion of the proteins into smaller peptides, then separation of the peptides based on electrostatic charge using strong anionic exchange chromatography. The peptides were further separated by molecular weight using high pressure liquid chromatography. Each of the individual peptides was detected and identified using mass spectrometry and database analysis. DNA analysis of the yeast's genome predicts 5027 proteins. The team identified 4,600 proteins, which is not quite the entire proteome. The remaining 400 are only expressed during S. pombe's mating state.
S. pombe is often used as a model organism to study DNA damage response and repair, cell division, stress responses and other aspects of cellular biology.
About Burnham Institute for Medical Research
Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top-four institutions nationally for NIH grant funding and among the top-25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit, public benefit corporation.